课题基金 / 基金详情

R&D CMV RELATED HEARING LOSS AND FEASIBILITY OF CMV SCREENING

R&D CMV RELATED HEARING LOSS AND FEASIBILITY OF CMV SCREENING
右
批准号:
8544381
负责人:
Suresh B Boppana
金额:
$59.15万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-07-01 至 2012-06-30

项目摘要

项目成果

Suresh B Boppana的其他基金

相似基金

相关文献

中文摘要
翻译
本合同的目的是:1)解决先天性巨细胞病毒的存在与长期听力学/耳科预后之间的关系;2)解决巨细胞病毒筛查在新生儿永久性听力障碍检测中的临床有效性和实用性,以及在婴儿期或生命早期发病的听力障碍的预测。目的是将出生时巨细胞病毒状态与永久性和/或进行性感音神经性听力损失的存在联系起来;了解巨细胞病毒相关听力损失的发生率、病程和听力学结果;并确定巨细胞病毒筛查在多大程度上可以改善现有或进行性听力损失的检测和预测,如果结合已经用于新生儿听力筛查的生理指标。
英文摘要
The purpose of this contract is to 1) address the relationship between the presence of congenital CMV and long-term audiologic/otologic outcome, and 2) address the clinical validity and utility of CMV screening in the detection of permanent hearing impairment in the newborn, as well as the prediction of hearing impairment with onset during infancy or in the early years of life. The goals are to correlate CMV status at birth with the presence of permanent and/or progressive sensorineural hearing loss; to acquire information on the incidence, time course and audiologic outcomes of CMV related hearing loss; and to determine the extent to which CMV screening can improve detection and predictions of either existing or progressive hearing loss if combined with physiological metrics already in use for newborn hearing screening.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Adaptive Immunity and Persistent SARS-CoV-2 Replication
Adaptive Immunity and Persistent SARS-CoV-2 Replication
Adaptive Immunity and Persistent SARS-CoV-2 Replication
Adaptive Immunity and Persistent SARS-CoV-2 Replication
海外基金